Hepatitis C Virus Seroconversion Among Hemodialysis Patients and the Role of Hepatitis C Virus Positive Patient's Isolation in Benha, Egypt
Clinical Medicine Research
Volume 6, Issue 2, March 2017, Pages: 31-36
Received: Jan. 7, 2017; Accepted: Feb. 6, 2017; Published: Mar. 2, 2017
Views 1622      Downloads 64
Authors
Mohamed El–Tantawy Ibrahim, Internal Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt
Mona Ahmed Elawady, Public Health Department, Faculty of Medicine, Benha University, Benha, Egypt
Article Tools
Follow on us
Abstract
The prevalence of hepatitis C virus (HCV) infection in hemodialysis units (HD) is higher than among normal population. Seroconversion was included in many previous studies which constitute a great problem against infection control policies. The aim of this study was to evaluate seroconversion rate and the effect of isolation of hepatitis C positive patients as infection control method. This is controlled prospective study that included 90 patients for 2 years. Isolation policy of hepatitis C positive patients was implemented in the second year of the study. The prevalence of HCV was 48.9% among hemodialysis patients. Seroconversion rate decreased from 15.2% in the first year to 5.1%in the second year after application of isolation. The duration of hemodialysis in months, positive history of blood transfusion and the amount of transfused blood were considered significant factors affecting seroconversion. so we concluded that Isolation of hepatitis C positive patients as an infection control policy is mandatory to control HCV seroconversion in Egypt.
Keywords
HCV, Isolation, Seroconversion and HD
To cite this article
Mohamed El–Tantawy Ibrahim, Mona Ahmed Elawady, Hepatitis C Virus Seroconversion Among Hemodialysis Patients and the Role of Hepatitis C Virus Positive Patient's Isolation in Benha, Egypt, Clinical Medicine Research. Vol. 6, No. 2, 2017, pp. 31-36. doi: 10.11648/j.cmr.20170602.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Perico N, Cattaneo D, Bikbov B and Remuzzi G: Hepatitis C infection and chronic renal diseases. Clin J Am SocNephrol. 2009;4 (1): 207-20.
[2]
Bello AK, Nwankwo E and El Nahas AM: Prevention of chronic kidney disease: a global challenge. Kidney Int 2005; 98: 11–17.
[3]
Paez Jimenez A, Mohamed MK, SharafEldin N, AbouSeif H, El Aidi S, Sultan Y, Elsaid N, Rekacewicz C, El-Hoseiny M, El-Daly M, Abdel-Hamid M and Fontanet A: Injection drug use is a risk factor for HCV infection in urban Egypt. PloS One. 2009; 4: e7193.
[4]
Hahn JA: Sex, drugs and hepatitis C Virus. J Infect Dis. 2007 Jun 1; 195 (11): 1556-9.
[5]
Galperim B, Mattos AA, Stein AT, Schneider NC, Buriol A, Fonseca A, Lunge V and Ikuta N: Hepatitis C in hemodialysis: the contribution of injection drug use. The Brazilian Journal of Infectious Diseases. 2010; 14 (4): 422-6.
[6]
Khan S, Attaullah S, Ali I,Ayaz S, Naseemullah, Khan SN, Siraj S and Khan J: Rising burden of Hepatitis C Virus in hemodialysis patients. J Virol. 2011; 8: 438.
[7]
Fabrizi F., Messa P. and Martin P.: Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs. 2008; 31 (12): 1004-16.
[8]
Afifi A.: The Egyptian Renal Registry. The 9th annual report for the year 2008 Published on 29th Annual congress of nephrology of Egyptian Society of Nephrology and Transplantation ESNT Hurghada Egypt 2009.
[9]
Egyptian Renal Registry: 2008 report, ESNT congress, Hurghada Egypt, February, 2009.
[10]
Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S and Goubau P; HCV Collaborative Group: The changing epidemiology of hepatitis C virus (HCV) infection in hemodialysis, European multicentre study. Nephrol Dial Transplant. 2004; 19 (4): 904-9.
[11]
Bravo Zuñiga JI, LozaMunárriz C and López-Alcalde J: Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database of Systematic Reviews 2016, 8. Art. No.: CD006420.
[12]
Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, Couroucé AM, Astagneau P, Buisson C, Desenclos JC.: Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infec Control HospEpidemiol2002; 23 (6): 328-34.
[13]
Al-Jiffri AM, Fadeg RB, Ghabrah TM and Ibrahim A.: Hepatitis C virus infection among patients on hemodialysis in Jeddah: A single center experience. Saudi J Kidney Dis Transplant. 2003; 14 (1): 84–9.
[14]
Goldberg D and Anderson E.: Hepatitis C: Who is at risk and how do we identify them? J Viral Hepatitis. 2004; 11 (1): 12–8.
[15]
Iwasaki Y, EsumiM, HosokawaN, YanaiM, and KawanoK: Occasional infection of hepatitis C virus occurring in hemodialysis units identified by serial monitoring of the virus infection, Journal of Hospital Infection, 2000; 45 (1): 54–61.
[16]
Schneeberger PM, Keur I, Van Loon AM, Mortier D, De Coul KO, Van Haperen AV, Sanna R, Van Der Heijden TG, Van Den Hoven H, Van Hamersvelt HW, Quint W and Van Doorn LJ: The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study,” Journal of Infectious Diseases, 2000; 182 (5): 1291–9.
[17]
Nasser ME, Younes KM, Sany DH, Youssef SS, Mahmoud M and El-Sayed BS: HCV Seroconversion in two Egyptian Hemodialysis Units: Role of Detection Method and Patients Isolation, Macedonian Journal of Medical Sciences, 2014; 2 (1): 124-127.
[18]
Zahran AM: Prevalence of seroconversion of hepatitis C virus among hemodialysis patients in Menoufia Governorate, Egypt.Arab J Nephrol Transplant 2014, 7 (2): 133-5.
[19]
Khodir SA, Alghateb M, Okasha KM and Shalaby SS: Prevalence of HCV Infections Among Hemodialysis Patients in Al Gharbiyah Governorate, Egypt, Arab J Nephrol Transplant. 2012; 5 (3): 145-7.
[20]
Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. United States Renal Data System, USRDS 2011. Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. AJKD 2012; 59 (1): A7.
[21]
Stel VS, van de Luijtgaarden MW, Wanner C and Jager KJ; on Behalf of the European Renal Registry Investigators. The 2008 ERA-EDTA registry annual report-a précis. NDT Plus 2011; 4 (1): 1-13.
[22]
Elsharif ME and Elsharif EG: Causes of End-Stage Renal Disease in Sudan: A Single-Center Experience. Saudi J Kidney Dis Transpl 2011; 22 (2): 373-6.
[23]
United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal diseaseKidney Int Suppl. 2015; 5 (1): 2-7.
[24]
National Kidney Foundation, 2015: www.kidney.org
[25]
Ahmed HA, Yassinea YS, Tawafea AR and Ebazaway MM. Epidemiological study of patients on regular haemodialysis at the Kafer El-Shakh Governorate, Egypt. Menoufia Med J 2015; 28 (2): 267–71.
[26]
Abdelaali B, Omar M, Taoufik D, Samir A, Saad M and Benyahia M: Hepatitis C Viral Prevalence and Seroconversion in Moroccan Hemodialysis Units: Eight Year Follow Up. J Med Diagn Meth 2013; 2 (5): 2-5.
[27]
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W and Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;11; 355 (9207): 887-91.
[28]
Alashek WA, McIntyre CW and Taal MW: Hepatitis B and C infection in haemodialysis in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases 2012, 12:265.
[29]
Saxena AK and Panhotra BR: The vulnerability of middle aged and elderly patients to hepatitis C virus infection in a high-prevalence hospital-based hemodialysis setting. J Am Geriatr Soc. 2004; 52 (2): 242–6.
[30]
Ayman KARKAR: Hepatitis C in dialysis units: The Saudi Experience. Hemodialysis International 2007; 11 (3): 354–67.
[31]
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B,Hedderwick SA, Rayner HC, Greenwood RN, Akiba T and Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65 (6): 2335–42.
[32]
Soliman AR, AbdElaziz MM and El lawindi MI: Evaluation of an Isolation Program of Hepatitis C Virus Infected Hemodialysis Patients in Some Hemodialysis Centers in Egypt. ISRN Nephrology 2013; Article ID 395467: 1-5.
[33]
OˈBrien SF, Yi QL, Fan W, Scalia V, Kleinman SH and Vamvakas EC: Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services,” Transfusion 2007; 47 (2): 316–25.
[34]
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73 (109): 1–99.
[35]
Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W and MulhimKA: Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the Middle East. Am J Infect Control. 2003; 31 (1): 26–33.
[36]
Gallego E, López A, Pérez J, Llamas F, Lorenzo I, López E, Illescas ML, Andrés E, Olivas E, Gómez-Roldan C.: Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron ClinPract. 2006; 104 (1): 1-6.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186